Clinical Trials on Multiple Myeloma Progression

Total 13434 results

Instituto de Seguridad y Servicios Sociales de...

Unknown

Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans (MM-POM-2018)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

Mexico
Lawson Health Research Institute
The Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health System

Active, not recruiting

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)

Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage III

Canada
Genesis Pharma S.A.

Completed

A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease (LEGEND)

Relapsed/Refractory Multiple Myeloma

Greece
Icahn School of Medicine at Mount Sinai
Columbia University; New York Stem Cell Foundation Research Institute

Completed

Mitochondrial Dysfunction and Disease Progression

Clinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Mundipharma-EDO GmbH

Terminated

Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1)

Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Progression

Switzerland, United States, Norway
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Peng Liu
Shanghai East Hospital; Hrain Biotechnology

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Opexa Therapeutics, Inc.

Completed

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (Abili-T)

Multiple Sclerosis | Autoimmune Diseases of the Nervous System | Disease Progression | Secondary Progressive Multiple Sclerosis | Brain Atrophy

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Multiple Myeloma

United States, United Kingdom, Canada, Israel, France, Austria, Belgium, Germany, Ireland, Italy, Netherlands, Spain, Sweden
University of Minnesota
Mallinckrodt

Terminated

ACTH in Progressive Forms of MS

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple Sclerosis

United States
University of Pennsylvania

Recruiting

CART-38 in Adult AML and MM Patients

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM)

United States
Rebecca Spain

Completed

Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis

Progressive Multiple Sclerosis | Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
University of California, Los Angeles

Unknown

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Relapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple Sclerosis

United States
Brigham and Women's Hospital
Massachusetts General Hospital

Recruiting

Novel Assessment of Synaptic Density in Progressive MS

Multiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Johns Hopkins University

Completed

A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Rigshospitalet, Denmark
University of Copenhagen; Biogen; Copenhagen University Hospital, Hvidovre; Signifikans...

Completed

Natalizumab Treatment of Progressive Multiple Sclerosis (NAPMS)

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Denmark
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
Queen Mary University of London
Takeda Pharmaceuticals International, Inc.

Recruiting

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis (SIZOMUS)

Relapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United Kingdom
University of California, Los Angeles

Recruiting

Metformin Treatment in Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
University College Dublin

Completed

A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Ireland
Innate Immunotherapeutics
National Multiple Sclerosis Society; Primorus Clinical Trials

Completed

Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

New Zealand
Rigshospitalet, Denmark
Odense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaborators

Recruiting

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis (DanNORMS)

Relapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Denmark
Tel-Aviv Sourasky Medical Center
Tel Aviv University

Not yet recruiting

CTFEA Myeloma Study

Myeloma Multiple | Metastatic Bone Tumor
Amgen

Active, not recruiting

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia

United States, Australia, Japan, Germany, Canada
Fundación de Investigación Biomédica - Hospital...
Haematology Service,

Unknown

Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)

Multiple Mieloma

Spain
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Recruiting

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis (INsIDER)

Multiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)

Switzerland
Eye Hospital Pristina Kosovo

Enrolling by invitation

Human Fresh Corneal Lenticule Implantation Criteria in Progressive Corneal Disease Using Relex-Smile (Relex-Smile)

Progressive Disease of Corneae

Kosovo
Tiziana Life Sciences LTD

Withdrawn

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
Benovus Bio, Inc.

Unknown

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (BBMPI03)

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Multiple Myeloma (MM) | Smoldering Multiple Myeloma (sMM)

United States
University Hospital, Antwerp
Hasselt University; University Hospital, Ghent; AZ Sint-Jan AV; National MS Center... and other collaborators

Recruiting

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary-progressive Multiple Sclerosis

Belgium
Atara Biotherapeutics

Terminated

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis (EMBOLD)

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States, Australia, Canada
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
University of Glasgow
NHS Ayrshire and Arran; AKM

Completed

The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.

Multiple Sclerosis, Progressive

United Kingdom
Weill Medical College of Cornell University
Genzyme, a Sanofi Company

Completed

Measuring Active Microglia in Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (CARAMEL 2)

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States

Clinical Trials on Multiple Myeloma Progression

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations